Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Children entities : Sanofi save search
AstraZeneca Expands Fasenra’s Label to Younger Children with Severe Asthma
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
label children astrazeneca
AstraZeneca Expands Fasenra’s Label to Children Aged 6 to 11 with Severe Asthma
Published: 2024-04-12 (Crawled : 12:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
label children astrazeneca
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.23%
H: 0.9%
C: -0.68%
praluent fda children genetic cholesterol approval treat injection
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Published: 2023-10-22 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.21%
H: 0.08%
C: -1.81%
dupixent children year one results show
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Published: 2023-10-22 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.21%
H: 0.08%
C: -1.81%
dupixent children year one results show
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
Published: 2023-10-18 (Crawled : 09:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -1.23%
H: 0.0%
C: 0.0%
tzield children diabetes potential
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
Published: 2023-08-18 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: -0.39%
H: 3.29%
C: 2.21%
fda disease children approval treatment
Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
Published: 2023-06-25 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
CTIC | $9.09 0.05% 11M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
| Email alert
Add to watchlist
children haemophilia
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
Published: 2023-06-25 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
| Email alert
Add to watchlist
children
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
Published: 2023-03-22 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.07%
H: 0.54%
C: -1.18%
evkeeza fda children cholesterol
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.71%
H: 0.05%
C: -0.64%
dupixent children six dermatitis approved
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.71%
H: 0.05%
C: -0.64%
dupixent children six dermatitis approved
Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB
Published: 2023-03-02 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.76%
H: 1.58%
C: 1.58%
topline children haemophilia positive results study
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
Published: 2023-03-02 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.76%
H: 1.58%
C: 1.58%
treatment children potential study
Global Diabetes Care Drugs Market Report 2022: Rising Prevalence of Type-1 and Type-2 Diabetes in Children Drives Growth
Published: 2023-02-22 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: 0.0%
NVO | News | $128.64 2.7% -1.37% 60K
|
Health Technology
|
| O: 0.63%
H: 0.48%
C: -0.17%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.32%
H: 1.47%
C: -0.15%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: 0.0%
care global report children diabetes growth market
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: -0.09%
H: 0.59%
C: -0.21%
ALNY | $146.07 0.19% 0.18% 0
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
treatment fda disease children review
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
YSG | $4.09 4.07% 30K
|
Manufacturing
YMM | $8.45 3.55% 210K
|
Transportation and Warehousing
ZTO | $20.765 2.59% 220K
|
Transportation
ABNB | $164.76 2.37% 130K
|
Administrative and Support and ...
ZYXI | $11.42 1.42% 2.6K
|
Health Technology
ZS | $178.715 1.02% 40K
|
Technology Services
AAOI | $11.37 0.98% 19K
|
Electronic Technology
Z | $43.93 0.69% 28K
|
Technology Services
ZM S | $62.02 0.65% 84K
|
Technology Services
ZI 4 | $15.86 0.13% 23K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.